Cardinal Capital Management Inc. Acquires 450 Shares of Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Cardinal Capital Management Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 45.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,450 shares of the biopharmaceutical company’s stock after buying an additional 450 shares during the quarter. Cardinal Capital Management Inc.’s holdings in Pfizer were worth $57,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sheets Smith Wealth Management increased its position in Pfizer by 0.6% during the third quarter. Sheets Smith Wealth Management now owns 47,993 shares of the biopharmaceutical company’s stock valued at $1,724,000 after acquiring an additional 272 shares during the last quarter. Tradition Asset Management LLC increased its position in Pfizer by 1.6% during the third quarter. Tradition Asset Management LLC now owns 17,878 shares of the biopharmaceutical company’s stock valued at $642,000 after acquiring an additional 274 shares during the last quarter. Liberty Wealth Management LLC increased its position in Pfizer by 3.4% during the third quarter. Liberty Wealth Management LLC now owns 8,470 shares of the biopharmaceutical company’s stock valued at $304,000 after acquiring an additional 278 shares during the last quarter. First Heartland Consultants Inc. increased its position in Pfizer by 2.5% during the third quarter. First Heartland Consultants Inc. now owns 11,435 shares of the biopharmaceutical company’s stock valued at $411,000 after acquiring an additional 281 shares during the last quarter. Finally, Thomasville National Bank increased its position in Pfizer by 0.4% during the fourth quarter. Thomasville National Bank now owns 82,248 shares of the biopharmaceutical company’s stock valued at $3,223,000 after acquiring an additional 290 shares during the last quarter. Institutional investors own 70.21% of the company’s stock.

A number of research analysts have recently commented on PFE shares. Bank of America started coverage on shares of Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target on the stock. ValuEngine upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Royal Bank of Canada started coverage on shares of Pfizer in a report on Monday, January 6th. They issued an “outperform” rating and a $46.00 price target on the stock. Credit Suisse Group restated a “hold” rating and issued a $41.30 price target on shares of Pfizer in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Nine research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $43.41.

NYSE PFE opened at $40.67 on Thursday. The company’s 50-day moving average price is $38.90 and its 200-day moving average price is $38.18. The company has a current ratio of 0.90, a quick ratio of 0.68 and a debt-to-equity ratio of 0.55. The stock has a market cap of $221.75 billion, a PE ratio of 13.56, a PEG ratio of 4.24 and a beta of 0.65. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $44.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.10%. The firm had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $12.37 billion. During the same period in the prior year, the business posted $0.78 earnings per share. The business’s revenue for the quarter was down 4.6% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.97 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 31st will be paid a $0.38 dividend. The ex-dividend date is Thursday, January 30th. This is a positive change from Pfizer’s previous quarterly dividend of $0.36. This represents a $1.52 dividend on an annualized basis and a yield of 3.74%. Pfizer’s dividend payout ratio is 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Why do earnings reports matter?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.